Absci
Absci and AstraZeneca forge AI partnership to discover cancer treatments
Absci, a frontrunner in generative AI antibody discovery, has partnered with biopharmaceutical giant AstraZeneca to leverage AI in the quest for a novel cancer treatment. This collaboration will capitalise on Absci’s Integrated Drug Creation platform—seamlessly integrating with AstraZeneca’s expertise in oncology, aiming to expedite the discovery of a potentially game-changing cancer therapy. Under the agreement,…